From Exposure to Insight: 20 Years of DMPK Innovation at WuXi AppTec

Before a medicine can change a life, it must first complete a remarkable yet critical journey, navigating absorption, distribution, metabolism, and excretion within the human body. This process, often described through drug metabolism and pharmacokinetics (DMPK), has long remained invisible yet decisive, determining the fate of drug candidates well before they reach patients.

In 2026, WuXi AppTec DMPK marks its 20th anniversary, offering a vantage point to reflect on how the discipline, as well as its role in drug discovery, has evolved. Once a checkpoint, DMPK has become an early-stage decision engine. Over the past two decades, WuXi AppTec DMPK has grown in tandem with industry innovation, deeply participating in the full journey of new drug design, optimization, and late-stage development translation.

From Gatekeeper to Guide: How WuXi AppTec DMPK Grew with the Evolution of Drug Discovery

WuXi AppTec DMPK enables global partners to design, optimize, and advance drug candidates with greater confidence by integrating pharmacokinetic insights across discovery and development. This capability has been built over two decades, evolving from a descriptive and evaluative function into a technical platform deeply embedded throughout the new drug R&D process. By systematically characterizing the absorption, distribution, metabolism, and excretion (ADME) properties of compounds, it provides critical support for the optimization and screening of candidate molecules.

This change is reflected not only in scientific advances but also in measurable improvements in R&D efficiency. While global late-stage development drug development success rates remain in the range of 10-12%, the nature of failure has shifted significantly. Historically, suboptimal pharmacokinetics and bioavailability accounted for up to 40% attrition in development ^[1,2]. Today, that figure has declined to single digits, a change widely attributed to earlier and more systematic integration of DMPK into discovery workflows. This shift marks a transition from reactive assessment to proactive design, where understanding how a molecule behaves in the body begins well before it enters the clinic.

Increasingly, DMPK is embedded at the point of design. It guides molecular optimization through insights into physicochemical properties, permeability, and metabolic stability, and enables the selection of compounds with more favorable in vivo profiles from the outset. Its role extends across the development continuum. It informs translational strategies from preclinical models to humans, supports dose selection and regimen design, enables prediction of drug–drug interactions, and forms a foundational component of regulatory submissions. In this way, DMPK has evolved into an integrative science that connects discovery with development and ultimately with patients.

“The real value of DMPK lies in taking patient medication needs as the ultimate goal, understanding a drug’s pharmacokinetic profile and research strategy requirements, and leveraging WuXi AppTec’s automated and information-driven DMPK platform, alongside our team of pharmacokinetic experts, to empower clients to bring drugs to patients faster, more accurately, and with higher quality,” says Dr. Liang Shen, Head of WuXi AppTec DMPK.

Amid the sweeping transformation of the industry, WuXi AppTec DMPK was established in 2006. Over the past two decades, the platform has grown in step with the field. It has expanded from foundational laboratory pharmacokinetic capabilities into a globally integrated platform spanning in vitro ADME, in vivo PK, metabolite identification, radiolabeled synthesis and ADME, bioanalysis, and late-stage development translation. Today, WuXi AppTec DMPK has established research sites across multiple regions worldwide and, leveraging its extensive experience, successfully supports thousands of IND and NDA programs.

Redefining the Paradigm: A New Chapter for DMPK in the Era of Novel Modalities

To address the growing complexity of emerging therapeutic modalities, WuXi AppTec DMPK has developed tailored pharmacokinetic strategies that respond to the unique challenges of next-generation drug classes, ensuring these molecules reach patients faster and with greater confidence.

If the evolution of DMPK has been shaped by better tools and earlier integration, its next transformation has been driven by a more fundamental shift: the changing nature of the drug itself. The rise of novel therapeutic modalities, including peptides, oligonucleotides, antibody-drug conjugates (ADCs), targeted protein degraders, mRNA therapeutics, and covalent drugs, has challenged many of the assumptions that once defined pharmacokinetics. These molecules often extend beyond traditional “drug-like” boundaries, raising new questions around stability, tissue distribution, payload release, and bioanalytical measurement. In response, WuXi AppTec DMPK has developed modality-specific evaluation strategies and coordinated platforms, supporting a broad range of emerging therapeutic formats. Rather than applying a single framework to increasingly complex molecules, tailored methodologies have been established for each modality.

For oligonucleotide therapeutics, where traditional small-molecule assays are insufficient, specialized platforms combine LBA assays with high-sensitivity LC-MS/MS approaches. These support accurate quantification, metabolite profiling, and tissue distribution analysis. Together, these capabilities reflect a broader shift in DMPK, moving from adapting legacy paradigms to actively redefining them to meet the demands of next-generation therapeutics.

In the realm of ADC development, therapeutic behavior depends on the coordinated characterization of multiple components: the antibody, linker, and cytotoxic payload. Each has its distinct pharmacokinetic profiles. Integrated PK and bioanalytical strategies enable simultaneous quantification of total antibody, conjugated payload, and released small-molecule toxins, providing a more complete understanding of exposure, stability, and efficacy.

Beyond enabling individual R&D programs, WuXi AppTec DMPK has also contributed to advancing the global scientific community by systematically sharing its accumulated experience, driving the community to move forward together. Drawing on extensive practical insights accumulated across the complex drug field, the team, in collaboration with Wiley, published the dedicated monograph Drug Metabolism and Pharmacokinetics: Frontiers, Strategies, and Applications, which focuses on DMPK research strategies for novel modalities and disease areas. Covering key sectors such as ADCs, peptides, and oligonucleotides, the book centers on core directions including in vitro and in vivo pharmacokinetics, metabolite identification and structural optimization, radiolabeled synthesis and ADME, and bioanalysis. Combined with a wealth of real-world case studies, it establishes a comprehensive new molecular DMPK research system. By openly sharing knowledge and practical experience, WuXi AppTec DMPK not only extensively supports its clients but also continuously drives the overall development and evolution of the DMPK discipline in the era of novel molecules.

Information-Driven Efficiency: Elevating Quality and Speed through Automation & Digitalization

In recent years, automation and information technologies have significantly reshaped the drug R&D paradigm. To meet the dual demands of “high-quality” and “high-speed” in new drug development, WuXi AppTec DMPK has leveraged automation and digital as its core engine, systematically transforming the concept of “Information-Driven Efficiency" into measurable productivity through comprehensive capability building. From deploying automated equipment across multiple sites and integrating cross-system software and hardware, to dynamically optimizing and efficiently allocating experimental workflows through information-driven scheduling systems, and to precisely analyzing complex molecular structures via the information-driven spectrum interpretation platform —— WuXi AppTec DMPK has established a full-chain closed loop from experimental management to result generation, breaking efficiency bottlenecks and making information-driven efficiency and quality improvement a reality. The advancement of core underlying capabilities provides solid backing for global partners to cut preclinical development cycles and reinforce early pipeline foundations.

In terms of automation, to break the limitations of standalone equipment, WuXi AppTec DMPK has built high-throughput integrated liquid handling workstations to seamlessly connect all stages of in vitro ADME experiments, enabling a “one-click” workflow. Meanwhile, the team introduced the Night Watcher, a high-throughput biological sample pretreatment system, enabling 24/7 automated processing of in vitro samples. This upgrade has not only significantly expanded laboratory capacity but also substantially reduced manual intervention, effectively minimizing human errors and ensuring high reproducibility and result accuracy. Furthermore, an advanced vision-based automated compound storage system streamlines compound receiving, identification, and inventory checking, creating a smart closed-loop management system covering the entire lifecycle from reception to final disposal. This integrated automation layout optimizes the full-chain workflow of samples and compounds, ensuring stable support for high-throughput in vitro and in vivo drugability assessments.

While automation liberates us from repetitive tasks, digital capabilities empower decision-making, driving breakthroughs in complex problem-solving. Facing the surge of novel molecular drugs and the growing challenges in complex structure elucidation, WuXi AppTec DMPK proactively launched TidesID, a one-stop compound identification platform. The platform can automatically analyze the structures of complex molecules, such as peptides and oligonucleotides, and accurately match them with mass spectrometry readings, greatly shortening project turnaround time.

Digital technologies is also reshaping the efficiency and accuracy of pharmacokinetic research: WuXi AppTec DMPK’s intelligent animal facility, relying on four core technologies including the Resource Management System (RMS), Internet of Things (IoT) platform, electronic cage tags, and chip collars, enables precise full-lifecycle management of animals, real-time linkage of equipment data, instant information updates and rapid individual identification. This facility effectively reduces resource misallocation and human errors, laying a solid foundation of precision and efficiency for in vivo research on complex drugs.

Moving forward, WuXi AppTec DMPK will continue to expand digital technical application scenarios, continuously pushing the boundaries of efficiency and delivery quality through technological innovation, and safeguarding the new drug development journey of global partners.

Looking Ahead: From 20 Years of Progress to the Next Chapter

As WuXi AppTec DMPK marks its 20th anniversary in 2026, the milestone offers not only a moment of reflection, but also an opportunity to look ahead. Over the past two decades, the journey has unfolded alongside the broader evolution of drug discovery. The field has become more predictive, more integrated, and more ambitious in its pursuit of new medicines. What was once a largely observational discipline primarily playing a validation role has evolved into one of the key contributors to how drugs are designed, optimized, and translated to patients.

Yet, the trajectory is far from complete. As novel modalities continue to push the boundaries, and as scientific and technological advances reshape how decisions are made across the development continuum, the role of DMPK will continue to evolve alongside the science it supports. For WuXi AppTec DMPK, the past 20 years have been defined not by a single breakthrough but by sustained collaboration, adaptability, and a commitment to enabling partners at every stage of discovery and development. The next chapter will likely demand even greater integration and innovation. The underlying goal, however, remains unchanged: to help bring better medicines to patients more efficiently and with greater confidence, in pursuit of a shared vision that “every drug can be made, and every disease can be treated.”

Committed to accelerating drug discovery and development, we offer a full range of discovery screening, preclinical development, clinical drug metabolism, and pharmacokinetic (DMPK) platforms and services. With research facilities in the United States (New Jersey) and China (Shanghai, Suzhou, Nanjing, and Nantong), 1,000+ scientists, and over fifteen years of experience in Investigational New Drug (IND) application, our DMPK team at WuXi AppTec are serving 1,600+ global clients, and have successfully supported 1,800+ IND applications.

Talk to a WuXi AppTec expert today to get the support you need to achieve your drug development goals.

References:

[1] Waring et al., (2015). An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat Rev Drug Discov, http://doi.org/10.1038/nrd4609

[2] Dowden and Munro, (2019). Trends in clinical success rates and therapeutic focus. Nat Rev Drug Discov, http://doi.org/10.1038/d41573-019-00074-z